THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the submission of a Biologics License Application or BLA with the United States Food and Drug Administration for ABP 501, a biosimilar candidate to Humira or adalimumab.
Amgen believes this submission is the first adalimumab biosimilar application submitted to the FDA and represents Amgen's first BLA submission using the 351(k) biosimilar pathway.
ABP 501 is a biosimilar candidate to adalimumab, an anti-TNF-? monoclonal antibody, which is approved in many countries for the treatment of various inflammatory diseases.
Amgen's BLA submission includes analytical, clinical and pharmacokinetic data. Phase 3 comparative efficacy and safety studies were conducted in both moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis. The Phase 3 studies met their primary endpoints showing clinical equivalence to adalimumab. Safety and immunogenicity of ABP 501 were also comparable to adalimumab. Data to support the transition of adalimumab patients to ABP 501 are included in the submission.
ABP 501 is a biosimilar candidate to adalimumab, an anti-TNF-? monoclonal antibody, which is approved in many regions for the treatment of various inflammatory diseases. The active ingredient of ABP 501 is an anti-TNF-? monoclonal antibody that has the same amino acid sequence as adalimumab. ABP 501 has the same pharmaceutical dosage form and strength as adalimumab (U.S.) and adalimumab (EU).
Copyright RTT News/dpa-AFX